Developer docs
API playgroundTry for free, no card

Search company profiles

Hemex

Full company profile

uuid000658r

Namestring
Hemex
Websiteurl
hemex.ch
Company typeenum
Private
Founded yearint
2015
Descriptiontext

Hemex AG is a Swiss private company headquartered in Liestal, Switzerland, founded in 2015 with a reported headcount of 101-250 employees. Its core functional offering is supporting clients in the development of pharmaceuticals and medical devices, positioning it as a development services and consulting partner for the European biomedical ecosystem. Pricing models, customer segments, and named client logos are not disclosed in available sources, and the revenue model is accordingly characterized as services-based without further granularity.

The firm's technology footprint centers on its participation as a partner in the SEARCH (Synthetic hEalthcare dAta goveRnanCe Hub) initiative, led by Trinity College Dublin and comprising 26 European partners with a €15.2 million program budget. Within this consortium Hemex contributes to synthetic healthcare data generation and AI tools aimed at diagnostics and personalized medicine, building applied exposure to generative AI for structured biomedical data and predictive analytics for clinical use cases. No standalone product portfolio, patents, certifications, or proprietary datasets are disclosed for Hemex itself.

Capital history includes three funding rounds dated 2015, 2018, and 2021, with only the inaugural 2015 round having a disclosed value (~$110k); subsequent round sizes are unreported. Leadership consists of CEO Pascal Winnen and President of the Board Paul Hadváry. Public ownership, investor composition, and detailed customer relationships remain undisclosed in available sources, constraining further inference about the go-to-market motion and revenue mechanics beyond a services-based model in pharma and medtech development.

Short descriptiontext

Hemex AG is a Swiss firm that helps clients develop pharmaceuticals and medical devices, and participates as a partner in the European SEARCH consortium on synthetic healthcare data generation and AI-driven diagnostics and personalized medicine.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersLiestal, Switzerland
HQ citystring
Liestal
HQ countrystring
Switzerland
HQ regionstring
Europe
Markets served

Serves global market

Keyword5 values
pharmaceutical consulting, medical device development, drug development services, biomedical consulting, healthcare innovation services
Industry2 codes
PRIMARYHLAGABAG
Drug Substance–Drug Product Integrated CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHDAAALAA
Synthetic Data Generation Platforms
Hardware, Technology & Telecom/Artificial Intelligence & Machine Learning/Synthetic Data, Data Labeling & Training Data Tools
NAICS code1 code
  • Medical Laboratories621511
SIC code2 codes
  • Services-Commercial Physical & Biological Research8731
  • Services-Medical Laboratories8071
Product category
Pharmaceutical and Medical Device Development Services
No data
Cost components5 values
Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Hemex AG is a Swiss-based services company that helps clients develop pharmaceuticals and medical devices. The firm provides development advisory and consulting support to companies in the biomedical ecosystem, and participates in collaborative initiatives such as the SEARCH (Synthetic hEalthcare dAta goveRnanCe Hub) consortium focused on synthetic healthcare data generation and AI tools for diagnostics and personalized medicine.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

Hemex appears to be involved as a partner in the SEARCH (Synthetic hEalthcare dAta goveRnanCe Hub) initiative led by Trinity College Dublin. However, the source data does not provide specific details about Hemex's own product portfolio or service offerings.

Product and service3 records
1Pharmaceutical Development Services
CategoryPharmaceutical Consulting
Description

Advisory and development support services that help pharmaceutical clients develop drugs and therapies. Targeted at pharmaceutical companies seeking expertise in drug development.

2Medical Device Development Services
CategoryMedical Device Consulting
Description

Advisory and development support services that help clients develop medical devices. Targeted at medical device companies and innovators in the biomedical ecosystem.

3SEARCH Synthetic Healthcare Data Governance Hub
CategoryHealthcare Data and AI Solutions
Description

Participative consortium offering involving synthetic healthcare data generation and AI tools for diagnostics and personalized medicine, developed in collaboration with Trinity College Dublin and 26 European partners.

Scale indicator2 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierLeadTypeStrategic or Co-development PartnerAnnounced on2024-10-01
Description

Trinity College Dublin leads the SEARCH (Synthetic hEalthcare dAta goveRnanCe Hub) initiative, which aims to accelerate healthcare innovation through synthetic data generation and secure data sharing in the biomedical ecosystem. The initiative focuses on developing AI tools for diagnostics and personalized medicine.

Recent move4 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Peers10 records
TypeEmerging player
Description

Health research network enabling real-world data access for clinical research and AI development. Overlaps with Hemex's biomedical data sharing and AI tooling themes, though focused on federated real-world data rather than synthetic data.

2Tempus Labs
TypeEmerging player
Description

AI-driven precision medicine company combining large-scale data with diagnostics and therapeutic development. Overlaps with Hemex's interest in AI tools for diagnostics and personalized medicine, but operates a data-centric product model.

TypeBroad incumbent
Description

Major clinical research and contract development organization serving pharma and medical device developers. Comparable to Hemex in helping clients bring drugs and devices to market, though with a global delivery footprint and broader service portfolio.

TypeBroad incumbent
Description

Global leader in life-sciences services, clinical research, and healthcare data analytics. Comparable to Hemex in serving pharma/medical device development clients with data-driven capabilities, but operating at vastly greater scale across the full value chain.

TypeEmerging player
Description

Specializes in synthetic, privacy-safe healthcare data for research and analytics. Direct functional comparable to Hemex's synthetic-data generation capability, with established deployments across hospital systems.

TypeEmerging player
Description

AI-driven biotech using federated learning on patient data to support diagnostics and drug discovery. Comparable to Hemex in combining AI capabilities with pharma/biomedical research customers, though focused on building its own AI products rather than services.

TypeEmerging player
Description

Specialist in synthetic healthcare data generation for biomedical research and AI development. Most direct functional comparable to Hemex's SEARCH-aligned capability, competing for the same emerging synthetic-data-for-healthcare opportunity.

TypeEmerging player
Description

Provides AI-driven access to real-world evidence for clinical and research decisions. Comparable to Hemex's AI-for-healthcare ambition, with a narrower but more productized focus on evidence generation.

TypeBroad incumbent
Description

Provides research models, discovery, and safety assessment services to pharma and medical device developers. Overlaps with Hemex's life-sciences development services positioning, though focused on early-stage research and preclinical work.

TypeBroad incumbent
Description

Clinical trial data platform used across pharma and medical device development. Comparable to Hemex in serving drug/device developers with data and analytics infrastructure, though embedded into the broader Dassault 3DEXPERIENCE portfolio.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks3 records

Each record includes

Headline, Details, Source

Key highlights5 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability3 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles2 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds3 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment13 records

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Hemex

Pharmaceutical and Medical Device Development Serviceshemex.ch

Hemex AG is a Swiss firm that helps clients develop pharmaceuticals and medical devices, and participates as a partner in the European SEARCH consortium on synthetic healthcare data generation and AI-driven diagnostics and personalized medicine.

What Hemex does

Hemex AG is a Swiss private company headquartered in Liestal, Switzerland, founded in 2015 with a reported headcount of 101-250 employees. Its core functional offering is supporting clients in the development of pharmaceuticals and medical devices, positioning it as a development services and consulting partner for the European biomedical ecosystem. Pricing models, customer segments, and named client logos are not disclosed in available sources, and the revenue model is accordingly characterized as services-based without further granularity.

The firm's technology footprint centers on its participation as a partner in the SEARCH (Synthetic hEalthcare dAta goveRnanCe Hub) initiative, led by Trinity College Dublin and comprising 26 European partners with a €15.2 million program budget. Within this consortium Hemex contributes to synthetic healthcare data generation and AI tools aimed at diagnostics and personalized medicine, building applied exposure to generative AI for structured biomedical data and predictive analytics for clinical use cases. No standalone product portfolio, patents, certifications, or proprietary datasets are disclosed for Hemex itself.

Capital history includes three funding rounds dated 2015, 2018, and 2021, with only the inaugural 2015 round having a disclosed value (~$110k); subsequent round sizes are unreported. Leadership consists of CEO Pascal Winnen and President of the Board Paul Hadváry. Public ownership, investor composition, and detailed customer relationships remain undisclosed in available sources, constraining further inference about the go-to-market motion and revenue mechanics beyond a services-based model in pharma and medtech development.

Hemex firmographics

Firmographics
Name
Hemex
Website
https://hemex.ch
Company type
Private
Founded year
2015
Operating status
Operating
Headcount range
11–50 employees
Short description
Hemex AG is a Swiss firm that helps clients develop pharmaceuticals and medical devices, and participates as a partner in the European SEARCH consortium on synthetic healthcare data generation and AI-driven diagnostics and personalized medicine.
Ownership category
akta.pro rank

Hemex industry classification

Industry
Product category
Pharmaceutical and Medical Device Development Services
NAICS
Medical Laboratories (621511)
SIC
Services-Commercial Physical & Biological Research (8731), Services-Medical Laboratories (8071)
akta.pro industry
PRIMARYHLAGABAG
Drug Substance–Drug Product Integrated CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHDAAALAA
Synthetic Data Generation Platforms
Hardware, Technology & Telecom/Artificial Intelligence & Machine Learning/Synthetic Data, Data Labeling & Training Data Tools

Keywords

  • Pharmaceutical consulting
  • Medical device development
  • Drug development services
  • Biomedical consulting
  • Healthcare innovation services

Where Hemex is headquartered

Location

Headquarters

HQ city
Liestal
HQ country
Switzerland
HQ region
Europe

Markets served

Hemex business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure

Hemex product offering

Product offering

Core offering

Hemex AG is a Swiss-based services company that helps clients develop pharmaceuticals and medical devices. The firm provides development advisory and consulting support to companies in the biomedical ecosystem, and participates in collaborative initiatives such as the SEARCH (Synthetic hEalthcare dAta goveRnanCe Hub) consortium focused on synthetic healthcare data generation and AI tools for diagnostics and personalized medicine.

Product overview

Hemex appears to be involved as a partner in the SEARCH (Synthetic hEalthcare dAta goveRnanCe Hub) initiative led by Trinity College Dublin. However, the source data does not provide specific details about Hemex's own product portfolio or service offerings.

Differentiator

Problem solved

Functional benefit

Products and services

  • Pharmaceutical Development Services Advisory and development support services that help pharmaceutical clients develop drugs and therapies. Targeted at pharmaceutical companies seeking expertise in drug development.
  • Medical Device Development Services Advisory and development support services that help clients develop medical devices. Targeted at medical device companies and innovators in the biomedical ecosystem.
  • SEARCH Synthetic Healthcare Data Governance Hub Participative consortium offering involving synthetic healthcare data generation and AI tools for diagnostics and personalized medicine, developed in collaboration with Trinity College Dublin and 26 European partners.

Companies that use Hemex

Customer profile

Ideal customer profiles2 records

Hemex technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability3 records

Hemex partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • Trinity College DublinleadStrategic or Co-development Partner · 1 October 2024Trinity College Dublin leads the SEARCH (Synthetic hEalthcare dAta goveRnanCe Hub) initiative, which aims to accelerate healthcare innovation through synthetic data generation and secure data sharing in the biomedical ecosystem. The initiative focuses on developing AI tools for diagnostics and personalized medicine.

Scale indicators2 records

Recent moves4 records

Expansion highlights4 records

Hemex competitors and assessment

Company assessment

Emerging players

  • TriNetX: Health research network enabling real-world data access for clinical research and AI development. Overlaps with Hemex's biomedical data sharing and AI tooling themes, though focused on federated real-world data rather than synthetic data.
  • Tempus Labs: AI-driven precision medicine company combining large-scale data with diagnostics and therapeutic development. Overlaps with Hemex's interest in AI tools for diagnostics and personalized medicine, but operates a data-centric product model.
  • MDClone: Specializes in synthetic, privacy-safe healthcare data for research and analytics. Direct functional comparable to Hemex's synthetic-data generation capability, with established deployments across hospital systems.
  • Owkin: AI-driven biotech using federated learning on patient data to support diagnostics and drug discovery. Comparable to Hemex in combining AI capabilities with pharma/biomedical research customers, though focused on building its own AI products rather than services.
  • Syntegra: Specialist in synthetic healthcare data generation for biomedical research and AI development. Most direct functional comparable to Hemex's SEARCH-aligned capability, competing for the same emerging synthetic-data-for-healthcare opportunity.
  • Atropos Health: Provides AI-driven access to real-world evidence for clinical and research decisions. Comparable to Hemex's AI-for-healthcare ambition, with a narrower but more productized focus on evidence generation.

Broad incumbents

  • ICON plc: Major clinical research and contract development organization serving pharma and medical device developers. Comparable to Hemex in helping clients bring drugs and devices to market, though with a global delivery footprint and broader service portfolio.
  • IQVIA: Global leader in life-sciences services, clinical research, and healthcare data analytics. Comparable to Hemex in serving pharma/medical device development clients with data-driven capabilities, but operating at vastly greater scale across the full value chain.
  • Charles River Laboratories: Provides research models, discovery, and safety assessment services to pharma and medical device developers. Overlaps with Hemex's life-sciences development services positioning, though focused on early-stage research and preclinical work.
  • Medidata Solutions (Dassault Systèmes): Clinical trial data platform used across pharma and medical device development. Comparable to Hemex in serving drug/device developers with data and analytics infrastructure, though embedded into the broader Dassault 3DEXPERIENCE portfolio.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks3 records

Key highlights5 records

Customer concentration

Hemex financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Hemex leadership team

Management profile

Number of profiles

Profiles2 records

Hemex funding detail

Funding detail

Funding overview

Funding rounds3 records

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Hemex M&A and investment

M&A and investment

M&A

Investments13 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Hemex

What does Hemex do?

Hemex AG is a Swiss-based services company that helps clients develop pharmaceuticals and medical devices. The firm provides development advisory and consulting support to companies in the biomedical ecosystem, and participates in collaborative initiatives such as the SEARCH (Synthetic hEalthcare dAta goveRnanCe Hub) consortium focused on synthetic healthcare data generation and AI tools for diagnostics and personalized medicine.

Is Hemex a public or private company?

Hemex is a private company. It is classified as unknown and is currently operating.

When was Hemex founded?

Hemex was founded in 2015. It employs 11 to 50 people.

Where is Hemex based?

Hemex is headquartered in Liestal, Switzerland, in the Europe region.

Who are Hemex's main competitors?

Emerging players on record are TriNetX, Tempus Labs, MDClone, Owkin, Syntegra and Atropos Health. Broad incumbents are ICON plc, IQVIA, Charles River Laboratories and Medidata Solutions (Dassault Systèmes).

Does Hemex have an API?

No public API is recorded for Hemex.

What industry is Hemex in?

Hemex's product category is Pharmaceutical and Medical Device Development Services. Its primary akta.pro industry code is HLAGABAG, Drug Substance–Drug Product Integrated CDMO, with a secondary code of HDAAALAA, Synthetic Data Generation Platforms. Its NAICS code is 621511 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
GlobeNewswireHemex expands Global Clinical Network Alliance to strengthen end-to-end CRO CapabilitiesHemex AG announced a Clinical Network Alliance with international partners to expand its global CRO capabilities. The alliance combines expertise in oncology, imaging, recruitment, and PK/PD, supported by over 130 experts and a QA team with regulatory inspections from major authorities. Partners include Kitsa, Shankus Hospitals, COD Research, and Shankus Enem.startupticker.chAnnaida obtains undisclosed pre-series A fundingAnnaida Technologies closed an oversubscribed pre-Series A round led by HEMEX to launch its micro magnetic resonance platform in the fertility market. The EPFL spinoff's Embryospin device is already generating research product revenues, and the capital will support R&D, regulatory validation, and marketing. The company aims to reduce miscarriages in assisted fertility.The Times of IndiaMylab, Hemex join hands for COVID-19 testing in IndiaMylab Discovery Solutions and Hemex Health launched the Gazelle PathoCatch COVID-19 FIA test in India, a point-of-care diagnostic for all variants. The test detects variants in 20 seconds and is under USFDA review for emergency use authorization. It will be launched in Africa and the Middle East later this year.startupticker.chCHF 7.25 million for a platform reducing the burden of sepsisHemotune AG has closed a CHF 7.25 million Series B1 funding round to advance the preclinical development of its HemoSystem blood purification platform for sepsis treatment. The investment, led by OCCIDENT with participation from existing and new investors including Zürcher Kantonalbank and HEMEX, will support the preparation of clinical trials for the technology.startupticker.chResistell enters clinical studiesResistell AG launched its Performance Evaluation Study of its nanomotion-based antibiotic susceptibility test at Lausanne University Hospital, with HEMEX collaborating. The study aims to validate the rapid diagnostic, which reduces time to results from days to hours, over 12 months. The company seeks clinical evidence to bring the technology to market.news.cision.comInQbator: A new start-up incubator and accelerator powered by BLKB, Hemex and LaunchpadBLKB, Hemex, and Launchpad launched inQbator, a start-up incubator and accelerator in Liestal, Switzerland, to support early-stage companies. The program offers customized coaching, mentoring, and discounted services, with access to office space and labs. Applications are open online, and a digital information event is scheduled for March 16, 2021.startupticker.chHEMEX closes an oversubscribed Series C financing roundHEMEX, a life science consulting and investment firm, closed an oversubscribed Series C round with contributions from Swiss entrepreneurs and private investors. The funds will strengthen its team, expand service offerings, and accelerate global expansion. The company has supported over 30 companies since 2015.Nordic 9Scailyte to raise pre-series A financing round with CHF 3.7 million led by Swisscom Ventures, joined by 4FO ventures, Hemex and investiere.Scailyte, a Swiss biotech, raised a CHF 3.7 million pre-series A round led by Swisscom Ventures, with participation from 4FO ventures, Hemex, and investiere. The funds will accelerate assay development and build its biomarker and IVD pipeline, including first clinical applications using single-cell biomarkers.